Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Opus Genetics, Inc. - Common Stock
(NQ:
IRD
)
5.710
-0.260 (-4.36%)
Streaming Delayed Price
Updated: 3:15 PM EDT, Sep 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Opus Genetics, Inc. - Common Stock
Unusual volume stocks are being observed in Thursday's session.
↗
September 10, 2026
Via
Chartmill
Wednesday's session: top gainers and losers
↗
September 09, 2026
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
September 09, 2026
Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF)...
Via
Benzinga
Top stock movements in today's session.
↗
September 09, 2026
Via
Chartmill
Gapping stocks in Wednesday's session
↗
September 09, 2026
Via
Chartmill
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst
↗
May 25, 2026
Opus Genetics (NASDAQ:IRD) is advancing a portfolio of gene therapies for inherited retinal diseases, with two programs already in the clinic and three more expected to enter clinical testing within...
Via
MarketBeat
Wondering what's happening in today's after-hours session?
↗
December 31, 2025
Via
Chartmill
12 Health Care Stocks Moving In Friday's After-Market Session
↗
November 07, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
November 06, 2025
Via
Benzinga
This Celestica Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
↗
October 16, 2025
Via
Benzinga
Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review
↗
July 18, 2025
Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reassess its development strategy.
Via
Benzinga
Viatris Eye Drops Data Shows Promise For Blurred Near Vision
↗
June 26, 2025
Viatris and Opus Genetics report MR-141 met efficacy and safety goals in Phase 3 VEGA-3 trial for presbyopia, with strong patient-reported benefits.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
June 20, 2025
Via
Benzinga
Unusual volume stocks in Tuesday's session
↗
June 03, 2025
Unusual volume stocks are being observed in Tuesday's session.
Via
Chartmill
Power Metallic Mines Inc. (TSXV: PNPN) (OTCQB: PNPNF): A Strategic Entry Point for Investors? More Stocks Inside
June 02, 2025
Via
AB Newswire
Topics
Electric Vehicles
Discover the top movers in Friday's pre-market session.
↗
March 21, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
March 18, 2025
Via
Benzinga
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
